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Introduction
In current practice, gonadotropin-releasing hormone
(GnRH) analogs are widely used to suppress endogenous
gonadotropins during ovarian stimulation. The “long
protocol” is generally the most effective and most
popular in controlled ovarian hyperstimulation (COH).
Major disadvantages of GnRH analogs are increased
gonadotropin dosage after prolonged pituitary sup-
pression and higher risk of ovarian hyperstimulation
syndrome (OHSS) [1]. GnRH analogs desensitize the
pituitary gonadotropin cell and reduce the number of
GnRH receptors. Furthermore, GnRH analogs initially
stimulate the release of gonadotropins (flare-up) and
complete pituitary suppression is only achieved after
2–3 weeks pretreatment when pituitary desensitization
occurs due to receptor downregulation.
Recently, GnRH antagonists have been used to pre-
vent the onset of premature luteinizing hormone (LH)
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SUMMARY
Objective: To determine the minimal effective daily dose of gonadotropin-releasing hormone (GnRH) antagonist
in lower-weight Asian women undergoing controlled ovarian hyperstimulation (COH).
Materials and Methods: A prospective randomized controlled trial of GnRH antagonist was performed. A total
of 58 women with body weight of 40–50 kg accepted COH and transvaginal embryo transfer. Patients were
divided into two groups: Group 1 patients (n = 28) were given a fixed cetrorelix dose of 0.2 mg/day; Group 2
patients (n = 30) were given a fixed cetrorelix dose of 0.15 mg/day. Cetrorelix was administered from menstrual
day 8 until the day of human chorionic gonadotropin (hCG) administration. Serum luteinizing hormone (LH)
and estradiol (E2) concentration were measured on the day of hCG administration. Gonadotropin dosages, LH
and E2 concentrations, retrieved oocyte and embryo numbers, ovarian hyperstimulation syndrome (OHSS),
embryo quality, and the rates of fertilization, implantation and pregnancy in both groups were compared.
Results: The clinical pregnancy/implantation rates in Group 1 were higher than those in Group 2 (28.6%/10.4%
vs. 20%/4.1%). The numbers of oocytes retrieved/Grade I–II embryos were higher in Group 1 than Group 2
(10.5/7.8 vs. 8.3/3.9). A lower percentage of LH surge and higher E2 levels on the day of hCG adminstration
were observed in Group 1 compared to Group 2 (5.9%/1,610.8 pg/mL vs. 26.7%/1,023.6 pg/mL). There were
no statistical differences between the two groups when comparing gonadotropin dosage and OHSS.
Conclusion: The lowest effective dosage of cetrorelix is 0.2 mg in COH and pituitary downregulation for lower-
weight Asian women. [Taiwanese J Obstet Gynecol 2006;45(4):317–320]
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surges during COH. GnRH antagonists allow a short
and simple treatment regimen for in vitro fertilization
(IVF) patients. GnRH antagonists act by competing with
native GnRH for GnRH receptor binding sites, resulting
in rapid suppression of gonadotropins. Another advan-
tage of GnRH antagonists is reduction of gonadotropin
dosage during ovarian stimulation programs and lower
risk of OHSS [2]. GnRH antagonists greatly reduce the
duration of pituitary downregulation and prevent adverse
events related to flare-up induced by GnRH analogs.
Development of third- and fourth-generation GnRH
antagonists have obtained favorable clinical results.
Cetrorelix (ASTA Medica GmbH, Frankfurt/Main,
Germany) or ganirelix (Organon, Oss, The Netherlands)
have been used in recent clinical studies [3,4]. Daily
administration of the GnRH antagonist (the so-called
multiple dose protocol) at its minimum effective dose
(0.25 mg/day subcutaneously) has been proven to be
safe and effective [5,6]. Clinical research on cetrorelix
started off with relatively high daily doses of 3 and
1 mg [3,4], but finally, the lowest effective daily dose
appeared to be 0.25 mg [6,7]. However, few studies
report trials of GnRH antagonists in Asians. There is
no literature dealing with GnRH antagonist doses 
≤ 0.2 mg for pituitary suppression during COH.
Furthermore, results from clinical trials of the use
of GnRH antagonists in Asian women are few. In gen-
eral, Asian women weigh less than Caucasian women.
Given racial and ethnic differences, it is logical to sus-
pect that Asians and Caucasians require different effec-
tive GnRH antagonist doses. Therefore, we aimed to
determine the minimum safe and effective dose of GnRH
antagonist for pituitary suppression in lower-weight
Asian women. To the best of our knowledge, this is one
of the first such reports in this field.
Materials and Methods
This trial was a phase III, open-label, prospectively ran-
domized study to assess the efficacy and safety of GnRH
antagonists in women undergoing COH. A total of 58
females from infertile couples who accepted COH, IVF
with intracytoplasmic sperm injection (ICSI) and trans-
vaginal embryo transfer (TV-ET) were included. Main
inclusion criteria were: age at least 18 years but not
older than 39 years; body weight between 40 and
50 kg; regular menstrual period, ranging from 24 to 35
days. Approval from the institutional review board was
obtained for the analysis of this series.
All patients who accepted cetrorelix (Serono, Rome,
Italy) were divided randomly into two groups: Group 1
patients (n = 28) were given a fixed cetrorelix dose of
0.2 mg/day; Group 2 patients (n = 30) were given a
fixed cetrorelix dose of 0.15 mg/day. Cetrorelix was
administered from menstrual day 8 until the day of
human chorionic gonadotropin (hCG) administration.
The COH protocol performed in both groups was 
as previously described [8]. In brief, during menstrual
days 3–7, younger patients (< 35 years old) took two
ampules (150 IU) of Gonal-F (Serono) daily, and older
patients (≥ 35 years old) took three ampules (225 IU)
of Gonal-F daily. Ultrasound examination and mea-
surements for serum estradiol (E2), follicle stimulating
hormone (FSH) and LH levels were performed on men-
strual days 3, 8, 10 and 12. If day 8 E2 was <100 pg/mL,
then the daily gonadotropins were increased to three
ampules (225 IU) of Gonal-F for younger patients and
four ampules (300 IU) of Gonal-F for older patients.
Criteria for cancellation included lower E2 level on
menstrual day 8 (< 50 pg/mL) and poor follicle growth
during COH.
Gonadotropin and cetrorelix administration con-
tinued until two or more follicles measured > 18 mm;
then hCG 5,000 IU (Serono) was administered. Serum
LH and E2 concentrations were tested on the day of
hCG administration. Oocytes were retrieved transvagi-
nally 34–36 hours later. Oocyte culture, insemination,
embryo transfer and cryopreservation were as previ-
ously described [9]. TV-ET was performed 72 hours
after oocyte retrieval. A maximum of four embryos were
transferred into each patient. Luteal phase was sup-
ported with hCG (2,500 IU/day) on days 1, 4 and 7
post-ET, and progesterone 400 mg (Utrogeston®) from
day 1 post-ET. Clinical pregnancy was defined as elevated
serum β-hCG 12 days after ET and visualization of a
gestational sac by ultrasound.
Personal data (age, weight, body mass index, cause
of infertility), gonadotropin dosage, and serum con-
centration of LH and E2 on the day of hCG adminis-
tration of the two groups were compared. Retrieved
oocyte and embryo numbers, development of OHSS,
embryo quality, and the rates of fertilization, implan-
tation and pregnancy in both groups were assessed
and compared. SAS software (SAS Institute Inc., Cary,
NC, USA) with t test and χ2 test were utilized for statis-
tical analyses. A p value < 0.05 was considered statisti-
cally significant.
Results
We observed a favorable outcome in Group 1 (0.2 mg
cetrorelix). The clinical pregnancy/implantation rates
in Group 1 were higher than those in Group 2 (28.6%/
10.4% vs. 20%/4.1%; Table). Furthermore, Group 1
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patients also appeared to have better quality embryos
and oocytes. The numbers of oocytes retrieved/grade
I–II embryos in Group 1 were higher than those in
Group 2 (10.5/7.8 vs. 8.3/3.9). A lower percentage of
LH surge and higher E2 levels on the day of hCG
adminstration were observed in Group 1 compared to 
Group 2 (5.9%/1,610.8pg/mL vs. 26.7%/1,023.6pg/mL;
Table). There were no statistical differences between
the two groups in mean age, causes and duration of
infertility, baseline FSH concentration, cancellation rate,
gonadotropin dosage and OHSS.
Discussion
GnRH antagonists have been developed in parallel
with GnRH analogs, but their development history has
been plagued by high incidences of histamine release
following injection. Over the past few years, preven-
tion of histamine-releasing activity has been achieved.
Third-generation GnRH antagonists (cetrorelix and
ganirelix) have been used in multiple-dose regimens in
women undergoing COH. Since antagonists immedi-
ately suppress gonadotropins by blocking GnRH recep-
tors, treatment may be restricted to those days when
premature LH surge is likely to occur. Investigators
have demonstrated that serum GnRH antagonist con-
centrations increase in a linear dose-proportional man-
ner and serum LH decreases in a dose-proportional
manner [10,11].
Recent studies revealed that maximal endogenous
LH suppression occurs about 4 hours after GnRH anta-
gonist administation [11]. Moreover, rapid recovery of
pituitary function was observed after discontinuation
of the GnRH antagonist [12]. This is due to the rela-
tively short elimination half-life (about 13 hours) of
GnRH antagonists [5]. These results suggest that the
degree of pituitary suppression can be adjusted by
changing the GnRH antagonist dose. However, contro-
versy remains about the real efficacy of GnRH anta-
gonist application. Some investigators demonstrated
decreased pregnancy rates in GnRH antagonist cycles
[13,14].
The advantages of GnRH antagonist treatment in
ovarian stimulation programs are reduced dosage of
gonadotropins and lower risk of OHSS. The minimum
dose necessary to suppress LH release without impairing
embryo development and implantation may be deter-
mined. To select the minimum effective daily dose of a
GnRH antagonist, a multicenter, double-blind, ran-
domized, dose-finding study was performed on 333
women and included six different dosages ranging
from 0.0625 to 2 mg [13,15]. This study showed that
a daily dose of 0.25 mg GnRH antagonist was a safe,
short and convenient treatment regimen for women
undergoing COH, and resulted in good clinical out-
come [13]. Borm and Mannaerts demonstrated that a
daily dose of 0.25 mg GnRH antagonist prevented LH
surge and led to a favorable outcome (37% ongoing
pregnancy rate) [5]. Few authors have reported a dosage
of GnRH antagonist ≤ 0.2 mg in pituitary suppression.
Regarding racial differences, most Asian women
appear to weigh less than Caucasian women. Therefore,
the GnRH antagonist dosage should be adjusted. In
this series, we first tried a lower dose for Asians with a
lower body weight. We observed that individuals with
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Table. Comparisons of gonadotropin-releasing hormone (GnRH) antagonist dosages, gonadotropin dosages, laboratory
data, ovarian hyperstimulation syndrome (OHSS), and clinical results in both groups
Variable
Group 1 Group 2
p
(Cetrorelix 0.2 mg; n = 28) (Cetrorelix 0.15 mg; n = 30)
Age 30.96 ± 2.92 30.07 ± 3.63 NS
BMI 19.21 ± 0.81 19.15 ± 0.84 NS
GnRH antagonist dosage 1.07 ± 0.28 0.763 ± 0.147 < 0.05*
Gonadotropin dosage 1,669.6 ± 409.3 1,856.7 ± 733.9 NS*
Oocytes retrieved, n 10.5 ± 5.1 8.3 ± 6.7 < 0.05*
Oocytes fertilized, n 9.2 ± 4.2 5.1 ± 2.4 < 0.05*
Grade I/II embryos 7.8 ± 4.8 3.9 ± 2.4 < 0.05*
E2 on hCG day (pg/mL) 1,610.8 1,023.6 < 0.05*
LH surge, n (%) 2 (5.9) 8 (26.7) < 0.05*
Chemical pregnancy, n (%) 10 (35.7) 7 (23.3) < 0.05*
Clinical pregnancy, n (%) 8 (28.6) 6 (20) < 0.05*
Implantation rate (%) 10.4 4.1 < 0.05*
OHSS 0 0 NS†
*t test; †c2 test. BMI = body mass index; E2 = estradiol; hCG = human chorionic gonadotropin; LH = luteinizing hormone; NS = non-significant difference.
a lower body weight (< 50 kg) should be considered
for a 0.2 mg daily dosage of cetrorelix. We also noted
that cetrorelix 0.15 mg daily is not suitable for LH sup-
pression. In this study, we noted that clinical pregnancy/
implantation rates in the 0.2 mg group were higher
than those in the 0.15 mg group. We also noted that
0.2 mg cetrorelix appeared to have a comparable preg-
nancy rate (around 30%) to that of 0.25 mg cetrorelix
found in previous studies [5,16]. The LH surge risk for
the 0.2 mg daily dose was as low as that of the 0.25 mg
trials.
In conclusion, 0.2 mg cetrorelix might be the low-
est effective dose in COH and pituitary downregulation
for lower-weight Asian women. A lower dosage of cetro-
relix might be unsuitable for pituitary suppression. 
A dosage of 0.2 mg cetrorelix should be considered for
individuals with a lower body weight. Regarding case
number limitation, a larger series might be necessary
to clarify related issues. Furthermore, the influence of
GnRH antagonists on pregnancy rate, synchronization
of follicles, and oocyte and embryo quality merits further
surveys. However, a bright future for the application of
GnRH antagonists is expected. Further application of
GnRH antagonists will allow a short and simple treat-
ment regimen for IVF patients undergoing COH.
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